Hiroaki Suga
Japanese chemist (born 1963)
Hiroaki Suga (菅 裕明, born February 21, 1963) is a Japanese biochemist and businessman. He is best known for his work on artificial ribozymes (flexizymes) and their application in mRNA display (RaPID, random nonstandard peptide integrated discovery).2
From Wikipedia’s article on Hiroaki Suga (this version), CC BY-SA 4.0.
Born 1963.1
About
Suga was awarded the 2023 Wolf Prize in Chemistry, jointly with Chuan He and Jeffery W. Kelly, "for pioneering discoveries that illuminate the functions and pathological dysfunctions of RNA and proteins and for creating strategies to harness the capabilities of these biopolymers in new ways to ameliorate human diseases."
From Wikipedia’s article on Hiroaki Suga, shared under CC BY-SA 4.0.2
Companies
- PeptiDreamFounder16
Early life and education
- 1990 to 1994Massachusetts Institute of Technology Doctor of Philosophy3
- Date not recordedOkayama University3
Suga graduated from Okayama University (BSc, MSc) in engineering, and studied at University of Lausanne, where he worked with Manfred Schlosser.
Suga completed his Ph.D. in chemistry at Massachusetts Institute of Technology in 1994 with Satoru Masamune, working on catalytic antibodies
From Wikipedia’s article on Hiroaki Suga (this version), CC BY-SA 4.0.
Career
Occupation: biochemist, university teacher, educator, researcher, chemist, businessperson.9
- Since 2003Worked at University of Tokyo4 7
- 1997 to 2003Worked at University at Buffalo4 6
- 1994 to 1997Postdoctoral researcher, Massachusetts General Hospital4 5
- Date not recordedWorked at University of Tokyo4
- Date not recordedFounded PeptiDream8
Scientific
After graduating from MIT with a Ph.D., Suga was a postdoctoral researcher at the Jack W. Szostak lab of Harvard Medical School before starting his independent career at University at Buffalo. Since 2003 he is a faculty member at the University of Tokyo.
Business
Suga is also a founder of PeptiDream Inc. Tokyo, a publicly traded biopharmaceutical start-up company responsible for discovering and developing non-standard peptide therapeutics in addition to addressing unmet medical needs as well as investigating peptide drug conjugates (PDC), peptides, and small molecule-based drugs. It is traded publicly on the Tokyo First Stock Exchange Market (the market capitalization is over JY 600 billions), which has many partnerships with pharmaceutical companies in worldwide.
Suga is chair of the editorial board at RSC Chemical Biology and associate editor at Angewandte Chemie.
From Wikipedia’s article on Hiroaki Suga (this version), CC BY-SA 4.0.
Personal life
Awards
Links
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1WikidataHiroaki Suga on Wikidata
- 2WikipediaHiroaki Suga on Wikipedia
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12WikidataHiroaki Suga: award, on Wikidata
- 13Wikidataaward, as reported
- 14Wikidataaward, as reported
- 15Wikidataaward, as reported
- 16WikidataPeptiDream, Founder